Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)

N/A

Report date: 2022/10/18 20:00:54

Base Information

Drug NameAnti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsAnti-BCMA
TargetsTumor necrosis factor ligand superfamily member 13B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEugia Pharma Specialities LtdActavis Inc
China Registration ClassN/A

Develop Information

Active CompaniesActavis IncEugia Pharma Specialities Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A